April 1, 2025 – Lawrence, KS – Design-Zyme LLC announces the award of additional funding from the Wellcome Leap Untangling Addiction initiative.  This funding will further develop DZ-XNF1, a revolutionary polydrug vaccine designed to combat Opioid Use Disorder.  This Wellcome Leap program aims to revolutionize the understanding and treatment of substance use disorders, addressing one of the most critical public health crises of our time.

​

Design-Zyme’s innovative vaccine represents a novel approach to tackling the opioid epidemic by combatting not only fentanyl but also xylazine, an adulterant frequently mixed into the street drug supply.  DZ-XNF1 represents a further leap forward by introducing an original approach to combatting the rising threat of nitazenes in the opioid crisis.  This new vaccine could play a crucial role in protecting vulnerable populations and reducing overdose deaths.  Funding from Wellcome Leap will enable DZ-XNF1 to continue preparation for planned clinical trials.   

 

About Design-Zyme LLC

Design-Zyme LLC is a biotechnology company focused on creating innovative solutions to some of the world’s most pressing health challenges. The company leverages cutting-edge science and technology to develop novel vaccines, therapeutics, and diagnostic tools, with a focus on addressing complex diseases and public health crises.

​

About Wellcome Leap

Wellcome Leap is a billion-dollar breakthrough engine for human health – at global scale. Founded by the Wellcome Trust in 2020 as a U.S. nonprofit, Wellcome Leap builds and executes bold, unconventional programs with the urgency required to deliver breakthroughs in years, not decades. Operating at the intersection of life sciences and engineering, Leap programs require best-in-class, multi-disciplinary, global teams assembled from universities, companies, and nonprofits working together to solve problems that they cannot solve alone. For more information visit www.wellcomeleap.org.